CoChat
Sign Up
Cited by 349Protease and Inhibitor MechanismsCellular Mechanics and InteractionsTGF-β signaling in diseases

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression

Open access
Brassart-Pasco, Sylvie, Brézillon, Stéphane, Brassart, Bertrand, Ramont, Laurent, Oudart, Jean-Baptiste, Monboisse, Jean Claude·2020·Frontiers in Oncology
DOI 10.3389/fonc.2020.00397PMC PMC7174611
Open this paper in CoChat — free accountOpen PDF

Abstract

The tumor microenvironment (TME) is composed of various cell types embedded in an altered extracellular matrix (ECM). ECM not only serves as a support for tumor cell but also regulates cell-cell or cell-matrix cross-talks. Alterations in ECM may be induced by hypoxia and acidosis, by oxygen free radicals generated by infiltrating inflammatory cells or by tumor- or stromal cell-secreted proteases. A poorer diagnosis for patients is often associated with ECM alterations. Tumor ECM proteome, also named cancer matrisome, is strongly altered, and different ECM protein signatures may be defined to serve as prognostic biomarkers. Collagen network reorganization facilitates tumor cell invasion. Proteoglycan expression and location are modified in the TME and affect cell invasion and metastatic dissemination. ECM macromolecule degradation by proteases may induce the release of angiogenic growth factors but also the release of proteoglycan-derived or ECM protein fragments, named matrikines or matricryptins. This review will focus on current knowledge and new insights in ECM alterations, degradation, and reticulation through cross-linking enzymes and on the role of ECM fragments in the control of cancer progression and their potential use as biomarkers in cancer diagnosis and prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2020.00397

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Main metabolic and extracellular matrix (ECM) alterations in the tumor microenvironment (TME) during tumor progression. During cancer progression, tumor cells increase lactate production, leading to an acidification of TME. Tumor cells, cancer-associated fibroblasts (CAFs), polymorphonuclear leukocytes (PMNs), and monocytes secrete proteases, such as matrix metalloproteinases (MMPs), that degrade ECM and release matrikines. CAFs induce a higher secretion of ECM macromolecules that leads to an excessive deposition of ECM components. Tumor cells, PMNs, and monocytes produce reactive oxygen species (ROS) that degrade ECM components and particularly collagen I, facilitating tumor cell migration. They also stimulate the production of MMPs. Hypoxia also induces hypoxia-inducible factor (HIF) stabilization, lysyl oxidase (LOX) and transglutaminase activation, collagen and elastin cross-linking leading to ECM stiffening. These events favor tumor cell migration and cancer progression.
Figure 1 Main metabolic and extracellular matrix (ECM) alterations in the tumor microenvironment (TME) during tumor progression. During cancer progression, tumor cells increase lactate production, leading to an acidification of TME. Tumor cells, cancer-associated fibroblasts (CAFs), polymorphonuclear leukocytes (PMNs), and monocytes secrete proteases, such as matrix metalloproteinases (MMPs), that degrade ECM and release matrikines. CAFs induce a higher secretion of ECM macromolecules that leads to an excessive deposition of ECM components. Tumor cells, PMNs, and monocytes produce reactive oxygen species (ROS) that degrade ECM components and particularly collagen I, facilitating tumor cell migration. They also stimulate the production of MMPs. Hypoxia also induces hypoxia-inducible factor (HIF) stabilization, lysyl oxidase (LOX) and transglutaminase activation, collagen and elastin cross-linking leading to ECM stiffening. These events favor tumor cell migration and cancer progression.CC BY · PubMed Central
Figure 2 Schematic representation of the main transduction pathways altered by extracellular matrix (ECM) bioactive fragments. Bioactive fragments stimulating the pathway are outlined in green, and fragments with inhibitory activity are outlined in red. Endostatin inhibits the Wnt/β-catenin pathway, while glypican-3 triggers this pathway. Tumstatin, tetrastatin, endostatin, NC1(XIX), and lumcorin inhibit the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway through integrin binding while VGVAPG and IKVAV activate this pathway through elastin receptor complex (ERC) and integrin binding, respectively. VGVAPG and IKVAV also activate the mitogen-activated protein kinase (MAPK) pathways. Arresten and canstatin activate the Bcl-2 pro-apoptotic pathway through integrin binding.
Figure 2 Schematic representation of the main transduction pathways altered by extracellular matrix (ECM) bioactive fragments. Bioactive fragments stimulating the pathway are outlined in green, and fragments with inhibitory activity are outlined in red. Endostatin inhibits the Wnt/β-catenin pathway, while glypican-3 triggers this pathway. Tumstatin, tetrastatin, endostatin, NC1(XIX), and lumcorin inhibit the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway through integrin binding while VGVAPG and IKVAV activate this pathway through elastin receptor complex (ERC) and integrin binding, respectively. VGVAPG and IKVAV also activate the mitogen-activated protein kinase (MAPK) pathways. Arresten and canstatin activate the Bcl-2 pro-apoptotic pathway through integrin binding.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 168 references

Cited by

Sorted by citations

See all 349

Related

Metadata

Authors
Brassart-Pasco, S., Brézillon, S., Brassart, B., Ramont, L., Oudart, J.-B., & Monboisse, J. C.
Affiliations
Centre National de la Recherche Scientifique (FR)
ORCID
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2020-04-15
Volume
10
Pages
397-397
ISSN
2234-943X (ISSN-L)
DOI
10.3389/fonc.2020.00397
PMC
PMC7174611
OpenAlex
W3016553015
Cited by
335
References
168
Citations by year
2026: 48 · 2025: 53 · 2024: 62 · 2023: 46 · 2022: 65 · 2021: 46 · 2020: 13
FWCI
4.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Centre National de la Recherche Scientifique (UMR 7369)
  • Université de Reims Champagne-Ardenne
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
tumor microenvironment, extracellular matrix, tumor progression, proteoglycans, matrikines, protease degradation, hypoxia, acidosis, cell invasion, metastasis, prognostic factors, angiogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review